Literature DB >> 23716980

A silybin-phospholipids complex counteracts rat fatty liver degeneration and mitochondrial oxidative changes.

Ignazio Grattagliano1, Catia V Diogo, Maria Mastrodonato, Ornella de Bari, Michele Persichella, David Q H Wang, Adriana Liquori, Domenico Ferri, Maria Rosaria Carratù, Paulo J Oliveira, Piero Portincasa.   

Abstract

AIM: To investigate the effectiveness of antioxidant compounds in modulating mitochondrial oxidative alterations and lipids accumulation in fatty hepatocytes.
METHODS: Silybin-phospholipid complex containing vitamin E (Realsil(®)) was daily administered by gavage (one pouch diluted in 3 mL of water and containing 15 mg vitamin E and 47 mg silybin complexed with phospholipids) to rats fed a choline-deprived (CD) or a high fat diet [20% fat, containing 71% total calories as fat, 11% as carbohydrate, and 18% as protein, high fat diet (HFD)] for 30 d and 60 d, respectively. The control group was fed a normal semi-purified diet containing adequate levels of choline (35% total calories as fat, 47% as carbohydrate, and 18% as protein). Circulating and hepatic redox active and nitrogen regulating molecules (thioredoxin, glutathione, glutathione peroxidase), NO metabolites (nitrosothiols, nitrotyrosine), lipid peroxides [malondialdehyde-thiobarbituric (MDA-TBA)], and pro-inflammatory keratins (K-18) were measured on days 0, 7, 14, 30, and 60. Mitochondrial respiratory chain proteins and the extent of hepatic fatty infiltration were evaluated.
RESULTS: Both diet regimens produced liver steatosis (50% and 25% of liver slices with CD and HFD, respectively) with no signs of necro-inflammation: fat infiltration ranged from large droplets at day 14 to disseminated and confluent vacuoles resulting in microvesicular steatosis at day 30 (CD) and day 60 (HFD). In plasma, thioredoxin and nitrosothiols were not significantly changed, while MDA-TBA, nitrotyrosine (from 6 ± 1 nmol/L to 14 ± 3 nmol/L day 30 CD, P < 0.001, and 12 ± 2 nmol/L day 60 HFD, P < 0.001), and K-18 (from 198 ± 20 to 289 ± 21 U/L day 30 CD, P < 0.001, and 242 ± 23 U/L day 60 HFD, P < 0.001) levels increased significantly with ongoing steatosis. In the liver, glutathione was decreased (from 34.0 ± 1.3 to 25.3 ± 1.2 nmol/mg prot day 30 CD, P < 0.001, and 22.4 ± 2.4 nmol/mg prot day 60 HFD, P < 0.001), while thioredoxin and glutathione peroxidase were initially increased and then decreased. Nitrosothiols were constantly increased. MDA-TBA levels were five-fold increased from 9.1 ± 1.2 nmol/g to 75.6 ± 5.4 nmol/g on day 30, P < 0.001 (CD) and doubled with HFD on day 60. Realsil administration significantly lowered the extent of fat infiltration, maintained liver glutathione levels during the first half period, and halved its decrease during the second half. Also, Realsil modulated thioredoxin changes and the production of NO derivatives and significantly lowered MDA-TBA levels both in liver (from 73.6 ± 5.4 to 57.2 ± 6.3 nmol/g day 30 CD, P < 0.01 and from 27.3 ± 2.1 nmol/g to 20.5 ± 2.2 nmol/g day 60 HFD, P < 0.01) and in plasma. Changes in mitochondrial respiratory complexes were also attenuated by Realsil in HFD rats with a major protective effect on Complex II subunit CII-30.
CONCLUSION: Realsil administration effectively contrasts hepatocyte fat deposition, NO derivatives formation, and mitochondrial alterations, allowing the liver to maintain a better glutathione and thioredoxin antioxidant activity.

Entities:  

Keywords:  Fatty liver; Glutathione; Lipid peroxidation; Nitrosothiols; Nitrotyrosine; Thioredoxin

Mesh:

Substances:

Year:  2013        PMID: 23716980      PMCID: PMC3662940          DOI: 10.3748/wjg.v19.i20.3007

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  54 in total

1.  Uric acid and anti-TNF antibody improve mitochondrial dysfunction in ob/ob mice.

Authors:  Inmaculada García-Ruiz; Cristina Rodríguez-Juan; Teresa Díaz-Sanjuan; Pilar del Hoyo; Francisco Colina; Teresa Muñoz-Yagüe; José A Solís-Herruzo
Journal:  Hepatology       Date:  2006-09       Impact factor: 17.425

Review 2.  Tissue protection mediated by mitochondrial K+ channels.

Authors:  Heberty T F Facundo; Maynara Fornazari; Alicia J Kowaltowski
Journal:  Biochim Biophys Acta       Date:  2005-07-01

Review 3.  A critical reflection on the definition of metabolic syndrome.

Authors:  Giovanni Federspil; Enzo Nisoli; Roberto Vettor
Journal:  Pharmacol Res       Date:  2006-03-27       Impact factor: 7.658

4.  In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease.

Authors:  Anna Wieckowska; Nizar N Zein; Lisa M Yerian; A Rocio Lopez; Arthur J McCullough; Ariel E Feldstein
Journal:  Hepatology       Date:  2006-07       Impact factor: 17.425

5.  Thioredoxin and lipoic acid catalyze the denitrosation of low molecular weight and protein S-nitrosothiols.

Authors:  Detcho A Stoyanovsky; Yulia Y Tyurina; Vladimir A Tyurin; Deepthi Anand; Dhara N Mandavia; David Gius; Juliana Ivanova; Bruce Pitt; Timothy R Billiar; Valerian E Kagan
Journal:  J Am Chem Soc       Date:  2005-11-16       Impact factor: 15.419

6.  Glutathione peroxidase, thioredoxin, and membrane protein changes in erythrocytes predict ribavirin-induced anemia.

Authors:  Ignazio Grattagliano; Stefan Russmann; Vincenzo O Palmieri; Piero Portincasa; Giuseppe Palasciano; Bernhard H Lauterburg
Journal:  Clin Pharmacol Ther       Date:  2005-10       Impact factor: 6.875

7.  Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis.

Authors:  Yusuf Yilmaz; Enver Dolar; Engin Ulukaya; Semra Akgoz; Murat Keskin; Murat Kiyici; Sibel Aker; Arzu Yilmaztepe; Selim Gurel; Macit Gulten; Selim-Giray Nak
Journal:  World J Gastroenterol       Date:  2007-02-14       Impact factor: 5.742

Review 8.  Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it.

Authors:  Karima Begriche; Anissa Igoudjil; Dominique Pessayre; Bernard Fromenty
Journal:  Mitochondrion       Date:  2006-01-05       Impact factor: 4.160

Review 9.  Nonalcoholic steatohepatitis: recent advances from experimental models to clinical management.

Authors:  Piero Portincasa; Ignazio Grattagliano; Vincenzo O Palmieri; Giuseppe Palasciano
Journal:  Clin Biochem       Date:  2005-03       Impact factor: 3.281

Review 10.  Genetic influences in nonalcoholic fatty liver disease.

Authors:  Raphael B Merriman; Bradley E Aouizerat; Nathan M Bass
Journal:  J Clin Gastroenterol       Date:  2006-03       Impact factor: 3.062

View more
  13 in total

Review 1.  Mitochondria and Reactive Oxygen Species in Aging and Age-Related Diseases.

Authors:  Carlotta Giorgi; Saverio Marchi; Ines C M Simoes; Ziyu Ren; Giampaolo Morciano; Mariasole Perrone; Paulina Patalas-Krawczyk; Sabine Borchard; Paulina Jędrak; Karolina Pierzynowska; Jędrzej Szymański; David Q Wang; Piero Portincasa; Grzegorz Węgrzyn; Hans Zischka; Pawel Dobrzyn; Massimo Bonora; Jerzy Duszynski; Alessandro Rimessi; Agnieszka Karkucinska-Wieckowska; Agnieszka Dobrzyn; Gyorgy Szabadkai; Barbara Zavan; Paulo J Oliveira; Vilma A Sardao; Paolo Pinton; Mariusz R Wieckowski
Journal:  Int Rev Cell Mol Biol       Date:  2018-06-22       Impact factor: 6.813

2.  Silybin counteracts lipid excess and oxidative stress in cultured steatotic hepatic cells.

Authors:  Giulia Vecchione; Elena Grasselli; Adriana Voci; Francesca Baldini; Ignazio Grattagliano; David Qh Wang; Piero Portincasa; Laura Vergani
Journal:  World J Gastroenterol       Date:  2016-07-14       Impact factor: 5.742

Review 3.  Intestinal Barrier and Permeability in Health, Obesity and NAFLD.

Authors:  Piero Portincasa; Leonilde Bonfrate; Mohamad Khalil; Maria De Angelis; Francesco Maria Calabrese; Mauro D'Amato; David Q-H Wang; Agostino Di Ciaula
Journal:  Biomedicines       Date:  2021-12-31

4.  Quantitative proteomics analysis based on tandem mass tag labeling coupled with labeling coupled with liquid chromatography-tandem mass spectrometry discovers the effect of silibinin on non-alcoholic fatty liver disease in mice.

Authors:  Yichao Wang; Hang Zhao; Liying Yang; He Zhang; Xian Yu; Wenjie Fei; Yunfeng Zhen; Zhe Gao; Shuchun Chen; Luping Ren
Journal:  Bioengineered       Date:  2022-03       Impact factor: 6.832

Review 5.  Silymarin as a Natural Antioxidant: An Overview of the Current Evidence and Perspectives.

Authors:  Peter F Surai
Journal:  Antioxidants (Basel)       Date:  2015-03-20

6.  Improved absorption and in vivo kinetic characteristics of nanoemulsions containing evodiamine-phospholipid nanocomplex.

Authors:  Jiangbo Hu; Dilong Chen; Rong Jiang; Qunyou Tan; Biyue Zhu; Jingqing Zhang
Journal:  Int J Nanomedicine       Date:  2014-09-17

Review 7.  Silymarin/Silybin and Chronic Liver Disease: A Marriage of Many Years.

Authors:  Alessandro Federico; Marcello Dallio; Carmelina Loguercio
Journal:  Molecules       Date:  2017-01-24       Impact factor: 4.411

Review 8.  Liver Steatosis, Gut-Liver Axis, Microbiome and Environmental Factors. A Never-Ending Bidirectional Cross-Talk.

Authors:  Agostino Di Ciaula; Jacek Baj; Gabriella Garruti; Giuseppe Celano; Maria De Angelis; Helen H Wang; Domenica Maria Di Palo; Leonilde Bonfrate; David Q-H Wang; Piero Portincasa
Journal:  J Clin Med       Date:  2020-08-14       Impact factor: 4.241

Review 9.  Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies?

Authors:  Agostino Di Ciaula; Salvatore Passarella; Harshitha Shanmugam; Marica Noviello; Leonilde Bonfrate; David Q-H Wang; Piero Portincasa
Journal:  Int J Mol Sci       Date:  2021-05-20       Impact factor: 5.923

Review 10.  Protocols for Mitochondria as the Target of Pharmacological Therapy in the Context of Nonalcoholic Fatty Liver Disease (NAFLD).

Authors:  Ignazio Grattagliano; Agostino Di Ciaula; Jacek Baj; Emilio Molina-Molina; Harshitha Shanmugam; Gabriella Garruti; David Q-H Wang; Piero Portincasa
Journal:  Methods Mol Biol       Date:  2021
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.